Sørensen Anna Lynge, Hansen Rehne Lessmann, Jørgensen Peter Holmberg
Ugeskr Laeger. 2016 Sep 5;178(36).
Giant cell tumour of bone (GCTB) is an aggressive bone tumour causing bone destruction. GCTB requires surgical treatment, and severe cases have a high risk of functional morbidity. GCTB consists of receptor activator of nuclear factor kappa-B (RANK)-positive osteoclast-like giant cells. The formation and activity of these cells are mediated by the interaction with RANK ligand (RANKL) released from neoplastic stromal cells. Denosumab is a human monoclonal antibody which inhibits RANKL and impairs the growth of the GCTB. Several studies have described the ability of denosumab to downgrade the extent of surgical treatment and improve the functional outcome.
骨巨细胞瘤（GCTB）是一种导致骨质破坏的侵袭性骨肿瘤。GCTB需要手术治疗，严重病例存在较高的功能致残风险。GCTB由核因子κB受体激活剂（RANK）阳性的破骨细胞样巨细胞组成。这些细胞的形成和活性是通过与肿瘤基质细胞释放的RANK配体（RANKL）相互作用介导的。地诺单抗是一种人源单克隆抗体，可抑制RANKL并抑制GCTB的生长。多项研究描述了地诺单抗降低手术治疗范围并改善功能结局的能力。
